fda warning letters compounding semaglutide news warns about safety of 'off-brand' versions of Ozempic, Wegovy US FDA sends 25 letters

According to the treatment estimand results, retatrutide resulted in 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg) weight loss across the treatment arms (vs 3.9% with placebo)

Heterogeneity in study design, patient populations and specific GLP1RAs examined likely contributes to these inconsistencies

Only ~13 states cover GLP-1s for obesity under Medicaid

However, GLP-1 RAs may be considered to lower the CV risk in patients with T2D who have a high to very high risk of CVD, (class IIb, level C)

All products sold by Rejuvenate Peptides are provided strictly for research, laboratory, and investigational purposes only